Lilly is on a record $20B acquisition tear — buy the momentum as it builds beyond obesity drugs
Eli Lilly has already announced more than $20 billion worth of acquisitions in 2026 — a record spending pace for the company. Lilly is using its blockbuster obesity-drug profits to buy up new businesses and diversify beyond weight-loss drugs.
Idea
Eli Lilly is sitting on enormous profits from its obesity franchise and is aggressively deploying that cash — over $20 billion in acquisitions this year alone. This is the kind of strategic reinvestment that Wall Street loves: it signals management confidence and reduces the risk that Lilly is a one-drug story. When a mega-cap pharma company goes on a record buying spree, it tends to attract institutional money flows for months as the acquisitions get integrated and new revenue streams materialize. The stock's momentum is likely to persist as each new deal announcement acts as a fresh catalyst.